Impact of lenvatinib on OATP1B activity in patients with hepatocellular carcinoma
British Journal of Clinical Pharmacology · 16.11.2026
DOI: 10.1002/bcp.70921 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 16.11.2026. Verfasst von Ken Shiraiwa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Grant-in-Aid for Encouragement of Scientists from the Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Aims
Lenvatinib (LEN) inhibits organic anion transporting polypeptide 1B1 (OATP1B1) in vitro, raising concern about drug–drug interactions (DDIs). We evaluated the in vivo impact of LEN on OATP1B activity in hepatocellular carcinoma (HCC), using coproporphyrin‐I (CP‐I) as endogenous biomarker.
Methods
Twenty‐six patients with HCC received LEN in this prospective, single‐centre, observational study. Plasma CP‐I and total and unbound LEN concentrations were measured at baseline and for 24 h after the first dose. DDI risk was assessed using the ICH M12 basic static model. Changes from baseline were analysed using a linear mixed‐effects model on log‐transformed concentrations with Dunnett's multiple comparisons and expressed as geometric mean ratios (GMR) with 95% confidence intervals (CIs).
Results
No significant changes in plasma CP‐I from baseline were observed at any time point, regardless of OATP1B1 genotype or hepatic function (adjusted p ≥ .25 in all comparisons). Whole‐cohort GMRs ranged from 0.97 to 1.11, with upper limit of 95% CI not exceeding 1.30. Baseline CP‐I did not differ by genotype ( p = .578) but was higher in Child–Pugh B than A ( p = .013). Using the basic static model, the median estimated C max ,inlet,u‐to‐IC 50 ,u ratio was 0.009, well below the 0.1 threshold.
Conclusions
LEN did not significantly alter OATP1B activity in HCC patients, concordant with static model prediction that first‐dose unbound LEN concentrations were far below the threshold for OATP1B1 inhibition. LEN‐attributable OATP1B1‐mediated DDI risk is therefore low, although this does not account for the reduced baseline OATP1B function inherent to HCC. Caution is warranted when extrapolating these findings to preserved hepatic function.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan.
- Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.
ORCID-Profile: Ken Shiraiwa, Ryota Tanaka, Yosuke Suzuki, Ayako Oda, Ryosuke Tatsuta
Förderung
- Grant-in-Aid for Encouragement of Scientists from the Japan Society for the Promotion of Science
Zitieren
APA
Shiraiwa, K., Sueshige, Y., Tanaka, R., Suzuki, Y., Oda, A., Sato, H., Toyama, D., Abe, H., Tatsuta, R., Ohno, K., & Itoh, H. (2026). Impact of lenvatinib on OATP1B activity in patients with hepatocellular carcinoma. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70921
Vancouver
Shiraiwa K, Sueshige Y, Tanaka R, Suzuki Y, Oda A, Sato H, et al. Impact of lenvatinib on OATP1B activity in patients with hepatocellular carcinoma. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70921
BibTeX
@article{Shiraiwa2026,
author = {Shiraiwa, Ken and Sueshige, Yoshio and Tanaka, Ryota and Suzuki, Yosuke and Oda, Ayako and Sato, Haruki and Toyama, Daiki and Abe, Hironori and Tatsuta, Ryosuke and Ohno, Keiko and Itoh, Hiroki},
title = {Impact of lenvatinib on OATP1B activity in patients with hepatocellular carcinoma},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70921}
}
EUVIMED